BS_9NJHQE9F
medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- medulloblastoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- medulloblastoma
- overall_survival_months
- 4.204993429697766
- age_years
- 2.411
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.465
- MYC_TARGETS_V1+0.436
- G2M_CHECKPOINT+0.374
- MYC_TARGETS_V2+0.230
- OXIDATIVE_PHOSPHORYLATION+0.227
- DNA_REPAIR+0.220
- SPERMATOGENESIS+0.207
- MITOTIC_SPINDLE+0.128
- UNFOLDED_PROTEIN_RESPONSE+0.089
- PROTEIN_SECRETION+0.084
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.623
- INTERFERON_GAMMA_RESPONSE-0.607
- INFLAMMATORY_RESPONSE-0.591
- ALLOGRAFT_REJECTION-0.583
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.577
- IL6_JAK_STAT3_SIGNALING-0.568
- ANGIOGENESIS-0.565
- TNFA_SIGNALING_VIA_NFKB-0.546
- HEDGEHOG_SIGNALING-0.536
- NOTCH_SIGNALING-0.502
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_KVNGNETA | medulloblastoma | — | 0.976 |
| 2 | BS_JFB984RG | medulloblastoma | — | 0.972 |
| 3 | BS_K74PZET7 | medulloblastoma | — | 0.969 |
| 4 | BS_CHDGRYHJ | medulloblastoma | — | 0.969 |
| 5 | BS_Z7PKVY9J | medulloblastoma | — | 0.968 |
| 6 | BS_9M5XJ10G | medulloblastoma | — | 0.967 |
| 7 | BS_KYF0Q0E7 | medulloblastoma | — | 0.966 |
| 8 | BS_H4B5Y6S0 | medulloblastoma | — | 0.966 |
| 9 | BS_J8G4SH4Z | medulloblastoma | — | 0.961 |
| 10 | BS_HF3RNN2T | medulloblastoma | — | 0.960 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.465 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.436 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.374 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.230 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.227 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.220 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.207 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.128 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.089 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.084 | Remibrutinib | — uncovered |
| PEROXISOME | 0.024 | Idelalisib | — uncovered |